Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Cachexia Stories

2013-04-22 08:28:29

Company Fully Funded Through Completion of Phase II Squalamine Eye Drop Trial for Wet-AMD and Into 2015 NEW YORK, April 22, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced that Ohr raised approximately $5.05 million dollars from institutional and accredited shareholders through the exercise of Series B Warrants. The Company intends to use the net proceeds...

2013-03-21 08:29:53

Demonstrates Weight Maintenance and Increase in Patient Appetite and Quality Of Life NEW YORK, March 21, 2013 /PRNewswire/ -- Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients,...

2013-02-07 08:28:39

NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, announced today that Dr. Irach Taraporewala, Chief Executive Officer of Ohr Pharmaceutical, will be presenting at the 15(th) Annual BIO CEO and Investor 2013 conference, taking place at the Waldorf Astoria Hotel in New York City on February 11-12, 2013. Dr. Taraporewala's presentation will include an overview of...

2013-01-29 08:30:26

LUGANO, Switzerland and MEXICO CITY, January 29, 2013 /PRNewswire/ -- Swiss pharmaceutical Helsinn Group has granted Latin American specialty company Stendhal exclusive commercialization rights for Mexico, Venezuela, Colombia, Peru, Ecuador and most of Central American countries, to this novel ghrelin receptor agonist. Anamorelin is a new first-in-class, once daily drug being developed for the treatment of cachexia-anorexia in NSCLC, a serious multifactorial...

2013-01-03 16:23:17

AUSTIN, Texas, Jan. 3, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation by the FDA for its therapeutic monoclonal antibody MABp1 (CV-18C3) as a treatment to reduce the need for re-intervention after superficial femoral artery (SFA) revascularization. Strong positive results from a recent Phase II study demonstrated that treatment with MABp1 resulted in prolonged patency of the SFA and reduction in...

2013-01-03 08:27:20

NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, announced today that Dr. Irach Taraporewala, Chief Executive Officer of Ohr Pharmaceutical, will be presenting at the Biotech Showcase 2013 conference, taking place at The Parc 55 Hotel in San Francisco on January 7-9, 2013. Dr. Taraporewala's presentation will include an overview of Ohr's clinical wet-AMD...

2012-12-27 08:25:07

NEW YORK, Dec. 27, 2012 /PRNewswire/ -- Ohr Pharmaceutical Inc., a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets, announced today that it has published a letter to shareholders, available on the Company's website, from its Chief Executive officer, Dr. Irach B. Taraporewala, Ph.D. The letter states: Dear Shareholder, I would like to take this opportunity to share the progress we have made in 2012 and...

Inhibiting Natural Molecules Found In Body Could Prevent Muscle Loss
2012-12-19 15:09:07

Lee Rannals for redOrbit.com — Your Universe Online A study may be paving the way for finding ways to prevent muscle loss, obesity and diabetes. Researchers from Nanyang Technological University (NTU) found that by inhibiting a particular molecule produced naturally in the body, muscle loss due to aging or illness can be prevented. By blocking this same molecule, it triggers the body to go into a "fat-burning mode" which will fight obesity, and also treat the most common form of...

2012-11-20 12:28:00

AUSTIN, Texas, Nov. 20, 2012 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study in patients receiving MABp1 to reduce restenosis after percutaneous revascularization of the Superficial Femoral Artery (SFA). Patients receiving MABp1 demonstrated a 58 percent reduction in Major Adverse Cardiovascular Events (MACE) and 60 percent longer patency in treated vessels compared to control patients. This...

2012-10-29 11:25:32

AUSTIN, Texas, Oct. 29, 2012 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1a as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform. The Company...